Simplex Trading’s KalVista Pharmaceuticals KALV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-3,543
Closed -$49K 9536
2025
Q2
$40K Buy
+3,543
New +$43.3K ﹤0.01% 6144
2025
Q1
Sell
-35,125
Closed -$358K 9065
2024
Q4
$297K Buy
35,125
+33,041
+1,585% +$342K ﹤0.01% 4073
2024
Q3
$24K Buy
2,084
+869
+72% +$10.9K ﹤0.01% 6529
2024
Q2
$14K Sell
1,215
-2,211
-65% -$25.8K ﹤0.01% 7186
2024
Q1
$40K Buy
+3,426
New +$45.7K ﹤0.01% 6471
2023
Q4
Sell
-8,810
Closed -$80.2K 9328
2023
Q3
$84K Buy
8,810
+7,520
+583% +$76.8K ﹤0.01% 5267
2023
Q2
$11K Buy
1,290
+194
+18% +$1.79K ﹤0.01% 7317
2023
Q1
$8K Buy
+1,096
New +$8.18K ﹤0.01% 7725
2022
Q3
Sell
-577
Closed -$8.06K 10397
2022
Q2
$5K Buy
577
+511
+774% +$5.64K ﹤0.01% 8832
2022
Q1
$0 Buy
+66
New +$948 ﹤0.01% 10912
2021
Q4
Sell
-3,623
Closed -$88K 10934
2021
Q3
$88K Hold
3,623
﹤0.01% 6802
2021
Q2
$86K Buy
3,623
+2,376
+191% +$62.2K ﹤0.01% 6944
2021
Q1
$32K Sell
1,247
-6,323
-84% -$166K ﹤0.01% 7064
2020
Q4
$143K Buy
+7,570
New +$130K ﹤0.01% 5040

Other funds holding KALV

Simplex Trading's KALV Position: Q3 2025 in Review

Simplex Trading sold out of KalVista Pharmaceuticals (KALV) in Q3 2025, closing a stake of 3,543 shares — an estimated $49K sold.

Simplex Trading first reported a position in KALV in Q4 2020 and held it in 14 quarters. The position peaked at $297K in Q4 2024. 145 funds tracked by Wall St. Rank hold KALV as of Q3 2025.

  • Simplex Trading reported no remaining KalVista Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Simplex Trading sold 3,543 KalVista Pharmaceuticals shares in Q3 2025, an estimated $49K.
  • Simplex Trading first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • Simplex Trading's KalVista Pharmaceuticals position peaked at $297K in Q4 2024.
  • 145 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2025.

Based on Simplex Trading's 13F filing for Q3 2025, filed 12 Nov 2025.